From the Guidelines
The dose of Qulipta (atogepant) for migraine prevention is not specified in the provided evidence.
Migraine Prevention
- The evidence suggests several medications for migraine prevention, including erenumab, fremanezumab, and galcanezumab 1.
- Atogepant is suggested for the prevention of episodic migraine, but the dose is not provided in the guideline 1.
- Other medications suggested for migraine prevention include lisinopril, oral magnesium, topiramate, propranolol, and valproate 1.
Dosing Information
- Unfortunately, the provided evidence does not include dosing information for atogepant or other medications for migraine prevention.
- For accurate dosing information, it is recommended to consult the prescribing information or a reliable clinical resource.
From the FDA Drug Label
2.1 Recommended Dosage QULIPTA is taken orally with or without food. Episodic Migraine The recommended dosage of QULIPTA for episodic migraine is 10 mg, 30 mg, or 60 mg taken once daily. Chronic Migraine The recommended dosage of QULIPTA for chronic migraine is 60 mg taken once daily. The dose of Qulipta (atogepant) for migraine prevention is:
- 10 mg, 30 mg, or 60 mg once daily for episodic migraine
- 60 mg once daily for chronic migraine 2
From the Research
Dose of Qulipta (Atogepant) for Migraine Prevention
The dose of Qulipta (atogepant) for migraine prevention has been evaluated in several studies.
- Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that has been shown to be effective in reducing migraine frequency and improving functional outcomes 3, 4, 5, 6, 7.
- The studies have investigated various doses of atogepant, including 10 mg, 30 mg, and 60 mg once daily, as well as 30 mg and 60 mg twice daily 5.
- The results of these studies have consistently shown that atogepant is effective in reducing mean monthly migraine days (MMDs) and monthly headache days (MHDs) compared to placebo, with the 60 mg once daily dose showing the greatest reduction 3, 4, 5, 6.
- The 60 mg once daily dose of atogepant has been shown to be safe and well-tolerated, with common adverse events being mild to moderate, such as constipation and nausea 3, 4, 5, 6.
- The efficacy and safety of atogepant have been evaluated in various patient populations, including those with episodic migraine and chronic migraine, as well as those who have previously failed conventional oral preventive treatments 3, 4, 5, 6, 7.
Key Findings
- Atogepant 60 mg once daily has been shown to be effective in reducing MMDs and MHDs compared to placebo 3, 4, 5, 6.
- Atogepant has been shown to be safe and well-tolerated, with common adverse events being mild to moderate 3, 4, 5, 6.
- The efficacy and safety of atogepant have been evaluated in various patient populations, including those with episodic migraine and chronic migraine, as well as those who have previously failed conventional oral preventive treatments 3, 4, 5, 6, 7.